Patent · US Active

FGF21 conjugates and anti-diabetic uses thereof

US8722622B2 · kind B2 · utility

6Cited by

17References

21Claims

0Family size

Assignees

CovX Technologies Ireland Limited · IE
PFIZER INC. · US

Inventors

Tapan Das · Chesterfield, US
Tamara Shafer Hodge · Ballwin, US
Tetsuya Ishino · Boston, US
Nancy Levin · Encinitas, US
Moorthy Sitharamaiah Suriyanarayana Palanki · Encinitas, US
Erin Kristen Parsons · University City, US
Bernard N. Violand · Park Hills, US

Key dates

Filing date	Nov 4, 2011
Grant date	May 13, 2014
Priority date	—
Expiry date	Nov 4, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.